ADMA Biologics (ADMA) AI Stock Analysis

• Market Cap: $4.20B
• Dividend Yield: N/A
• Average Volume (3M): 2.85M
• Price to Earnings (P/E): 21.8
• Beta (1Y): 1.07
• Revenue Growth: 62.22%
• EPS Growth: N/A
• Country: US
• Employees: 685
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): 0.14
• Shares Outstanding: 238,734,250
• 10 Day Avg. Volume: 4,159,939
• 30 Day Avg. Volume: 2,852,796
• PEG Ratio: 0.31
• Price to Book (P/B): 5.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.46
• Enterprise Value/Market Cap: 0.20
• Enterprise Value/Revenue: 0.52
• Enterprise Value/Gross Profit: 3.46
• Enterprise Value/Ebitda: 1.77
• 1Y Price Target: $30.67
• Price Target Upside: 66.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 77 Outperform
• Price Target: $23.00 ▲(25.00%Upside)

ADMA Biologics' strong financial performance and positive earnings call outlook are the primary drivers of the stock score. Although technical indicators show mixed signals, the improved guidance and strategic initiatives, such as FDA approval and stock repurchase, highlight significant growth potential. Valuation remains moderate, supporting a favorable outlook for long-term investors.

Positive Factors

Financial Performance

The filing of ADMA's 10-K is seen as a clearing event, resolving previous accounting concerns and shifting focus to the expansion of ASCENIV.

Supply Chain

The recent long-term plasma contracts have alleviated supply concerns, supporting the growth potential for ASCENIV.

Negative Factors

Guidance and Expectations

Key triggers behind the sell-off were a more modest than expected 2025 guide, ambiguity on bullish implications of the enhanced supply agreements, and valuation friction.

ADMA Biologics Business Overview & Revenue Model

Company Description

ADMA Biologics (ADMA) is a biopharmaceutical company focused on the development, manufacturing, and commercialization of specialty plasma-derived biologics. The company's primary emphasis is on immune globulin products used to treat patients with immune deficiencies and other related conditions. ADMA operates in the healthcare sector, providing critical therapies for individuals with compromised immune systems.

How the Company Makes Money

ADMA Biologics generates revenue primarily through the sale of its plasma-derived products, including BIVIGAM and ASCENIV, which are used for treating immune deficiencies. The company operates a vertically integrated business model, managing the collection of plasma from its donation centers, the manufacturing process, and the distribution of its products. Key revenue streams include direct sales to hospitals, specialty pharmacies, and healthcare providers. ADMA also earns revenue through strategic partnerships and agreements that enhance its distribution and reach within the market. The focus on niche markets and the critical nature of its products contribute significantly to its financial performance.

ADMA Biologics Financial Statement Overview

Summary

ADMA Biologics demonstrates strong financial health with significant improvements in revenue growth and profitability. The company maintains a solid balance sheet with low leverage and high equity ratios, minimizing financial risk. Strong cash flow management supports its operations, although careful monitoring of cash reserves is advisable. Overall, the company is well-positioned within the Biotechnology industry, benefiting from improved financial metrics.

Income Statement

ADMA Biologics has shown impressive revenue growth, with a TTM increase in Total Revenue of 7.72% compared to the previous annual report. The company has achieved a Gross Profit Margin of 52.54% and a Net Profit Margin of 45.00% in the TTM period, indicating strong profitability. The EBIT and EBITDA margins at 33.08% and 34.46% respectively, further demonstrate efficient operational management. Overall, the income statement reflects a solid turnaround from previous losses, showcasing strong growth and profitability.

Balance Sheet

ADMA Biologics has a strong equity position, with Stockholders' Equity accounting for 73.13% of Total Assets in the TTM period. The Debt-to-Equity Ratio is 0.22, indicating a low reliance on debt financing, which mitigates financial risk. However, the decreasing cash and short-term investments over time warrant attention. The Return on Equity of 55.39% in the TTM period is exceptionally high, reflecting strong profitability relative to equity.

Cash Flow

The company has shown strong cash flow management with a Free Cash Flow to Net Income Ratio of 0.44 in the TTM period, indicating efficient conversion of income to cash. While Operating Cash Flow decreased slightly from the previous period, it remains robust and supports the company's operations. The Free Cash Flow Growth Rate shows a decrease compared to previous years, highlighting the need for cautious cash management in future periods.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	459.38M	426.45M	258.21M	154.08M	80.94M	42.22M
Gross Profit	241.40M	219.55M	88.94M	35.27M	1.17M	-19.07M
EBITDA	158.29M	147.69M	5.12M	-39.72M	-53.33M	-59.82M
Net Income	206.77M	197.67M	-28.24M	-85.18M	-84.45M	-87.61M
Balance Sheet
Total Assets	510.57M	488.68M	329.18M	348.46M	276.25M	207.67M
Cash, Cash Equivalents and Short-Term Investments	71.63M	103.15M	51.35M	86.52M	51.09M	55.92M
Total Debt	82.01M	82.12M	141.42M	154.44M	102.92M	97.67M
Total Liabilities	137.15M	139.66M	193.98M	196.49M	135.08M	119.42M
Stockholders Equity	373.42M	349.02M	135.21M	151.97M	141.17M	88.25M
Cash Flow
Free Cash Flow	90.66M	110.10M	3.82M	-73.42M	-125.88M	-114.73M
Operating Cash Flow	101.22M	118.67M	8.80M	-59.51M	-112.37M	-102.00M
Investing Cash Flow	-10.93M	-8.57M	-4.98M	-13.91M	-13.51M	-12.72M
Financing Cash Flow	-63.98M	-58.30M	-38.99M	108.85M	121.05M	143.90M

ADMA Biologics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADMA, the sentiment is Negative. The current price of 18.4 is below the 20-day moving average (MA) of 19.71, below the 50-day MA of 20.72, and below the 200-day MA of 18.86, indicating a bearish trend. The MACD of -0.71 indicates Positive momentum. The RSI at 40.52 is Neutral, neither overbought nor oversold. The STOCH value of 13.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADMA.

ADMA Biologics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADMA	77 Outperform	$4.20B	21.80	78.45%	―	62.22%	―
VRNA	68 Neutral	$8.10B	―	-72.73%	―	―	-157.53%
IONS	58 Neutral	$6.37B	―	-118.53%	―	-7.65%	-11.81%
ZLAB	56 Neutral	$4.17B	―	-32.05%	―	43.72%	28.63%
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
PCVX	50 Neutral	$4.27B	―	-19.66%	―	―	7.75%
CYTK	43 Neutral	$3.95B	―	435.49%	―	412.21%	1.75%

ADMA Biologics Corporate Events

ADMA Biologics Holds Annual Stockholders Meeting

On June 4, 2025, ADMA Biologics, Inc. held its Annual Meeting of Stockholders, where key decisions were made, including the election of two Class III directors, ratification of KPMG LLP as the independent public accounting firm for 2025, approval of executive compensation, and setting the frequency of future advisory votes on executive pay to annually. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder engagement.

The most recent analyst rating on (ADMA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.

ADMA Biologics Announces $500M Share Repurchase Program

In the first quarter of 2025, ADMA Biologics reported a significant financial performance with a 40% increase in total revenue and an 81% rise in adjusted EBITDA year-over-year. The company announced a $500 million share repurchase program and a debt reorganization that reduced its cost of debt by 1.1%. Additionally, the FDA approved ADMA’s yield enhancement production process, expected to boost production output by 20%, supporting revenue growth and margin expansion. The company has increased its revenue guidance for 2025 and 2026, projecting total annual revenues to exceed $1.1 billion by 2030.